Tag Archives: research

The End of Alzheimer’s? A revolutionary scientific advance to the cure

Interface Dynamics Control Corporation (IDCC) has completed the first phase of its decade-long Advanced Therapeutic Interventions Project, with the result that a new approach to arresting and curing Alzheimer’s disease and the other neurodegenerative diseases has been produced and verified. IDCC is now launching the Project’s second phase, which will validate the first phase findings.

Alzheimer’s disease is the sixth leading cause of death in the United States, with more than 5.1 million Americans currently affected. The direct cost of Alzheimer’s is greater than $200 billion annually, a number expected reach between $1.2 and $1.5 trillion by 2050. Indirect costs are substantial: more than 15 million caregivers delivered some 17.5 billion hours of unpaid care valued at more than $200 billion.

IDCC has discovered the mechanism of and means to control the protein misfolding, abnormal aggregation, and degradation processes associated with the degenerative and prion diseases. That mechanism is also implicated in the failure to clear toxic intracellular proteins and in the dysfunction of apoptotic (programmed cell death) pathways. It underlies the adverse functions of the neuroglia (glial cells), including microglia, which provide immune defense to the central nervous system (CNS) and maintain homeostasis and protection for neurons in the brain and the peripheral nervous system.

The process of neurodegeneration has not been understood previously, which has precluded the production of any arresting or curative procedures or drugs. The Project’s findings, however, should lead to the realization of a new class of curative procedures and pharmaceuticals which can be engaged to defeat the disease-initiating neurodegenerative insult, thereby introducing the possibility of preventing these devastating diseases. There are direct implications for the human cancers, but verification of those implications must await further experiments.

The first major activity under the Project’s second phase will be the production of a new class of active imaging system. That system will be utilized to demonstrate the activities and accessible control points of the process pathways which, when certain abnormal events occur, trigger the incipient causal mechanisms of disease. The Project is currently developing the staff and capitalization required for execution of its second phase.

About IDCC 
IDCC was founded thirteen years ago to produce definitive solutions to seemingly intractable problems of social and technological significance. It is privately held and maintains its projects and client identities in strict confidence unless and until information releases are authorized by competent authority.

Contact Details: Peter W. Atkinson
IDCC
4655 Logsdon Drive
Annandale, VA 22003-3564 USA
+1.703.879.7065
Peter@InterfaceDynamicsControl.com

Via EPR Network
More Healthcare press releases

Innovative Drug Discovery Business, Biosortia Pharmaceuticals, Lands Two Health Care Veterans

Kurt Dieck formerly SVP of Strategy and Business Execution at Cardinal Health, will lead early stage drug discovery business at Biosortia Pharmaceuticals. Dieck was named President and CEO in November 2012 and has quickly identified other key executives, including Dr. Guy Carter, former Natural Product head at Wyeth Pharmaceuticals, as his Chief Science Officer. In conjunction, other collaboration partners have joined the team, including NOAA (National Oceanic and Atmospheric Administration), NCI (National Cancer Institute) and key universities, to strategically accelerate the development of novel drug leads in the therapeutic areas of cancer, infectious diseases, inflammation and neurological disorders. Biosortia Pharmaceuticals has seen promising early results with dozens of novel compounds having already been requested, and are under evaluation with NCI and Eli Lilly.

Dieck has spent nearly 30 years in healthcare, including 18 years at Arthur Andersen as a global equity partner and then 10 years with Cardinal Health, a Fortune 20 public company, as a senior executive; there he worked with a broad spectrum of partners, including brand pharmaceutical manufacturers, throughout the supply chain. Dr. Guy Carter has over 30 years of experience working in pharmaceutical R&D, primarily in the discovery and development of microbial natural products. He previously was the leader of natural products drug discovery at Wyeth Research, as head of the Chemical Technologies Department.

“Kurt and Guy make a great team. Their complementary Pharma experiences and backgrounds create great opportunities to accelerate Biosortia’s objective to become the premier, aquatic natural products company with a primary focus in drug discovery,” says Ross Youngs, Biosortia’s Founder and Chairman. “Kurt and Guy bring a wealth of research and business experience along with deep industry relationships in building successful Pharma partnerships. Everyone involved with this young biotech is excited about the future.”

Industry observers have commented that late-stage R&D pipelines are not providing Pharma with the desired revenue growth the market is expecting. Therefore, large Pharma is evolving the way it performs R&D in order to optimize efficiency and to boost patent cliff defenses. These changes require shifting from relying solely on in-house chemistry-based R&D to acquiring and licensing external technologies and natural products based compounds in various stages of development. Biosortia’s ability to supply novel, highly active and potent compounds with drug-like characteristics will increase the productivity and success rate for Pharma as well as reduce the overall cost of the discovery process. The cost to discover, develop and launch a new drug is estimated to reach nearly $3B per drug by 2015. Biosortia’s business model is designed specifically to support Pharma’s needs.

“With nearly unlimited microorganisms (3.7 nonillion), the aquatic environment and its consortia represent an extraordinary opportunity…a new frontier, to access extremely potent and chemically diverse secondary metabolites with drug-like properties with unique mechanisms of action never researched before,” said Dieck. In describing the opportunity, Dieck goes on to say, “Biosortia is on the cutting edge of natural product discovery
and has the capabilities to deliver on its aspiration. Our powerful natural products research team, led by Dr. Guy Carter, in partnership with NOAA’s Dr. Peter Moeller, a leader in aquatic natural products research, has the experience and know-how to decipher the complex unexplored environment in a very efficient manner leveraging all the current state of the art instrumentation. The need for more efficient and effective approaches to drug discovery has never been more important. Biosortia’s innovative technologies, deep research skills and key relationships will efficiently provide thousands of unique natural products as candidates for drug discovery at a time when Pharma is in critical need for “high quality shots on goal.”

“Aquatic microbial consortia are a rich source of metabolically active organisms including microalgae, bacteria, fungi and their secondary metabolites,” states Carter. “Owing to the competitive nature of their habitat, chemical investigations of microbial consortia reveal unique structurally diversified natural products that are responsible for signaling and self-defense that have potential as therapeutics with novel mechanisms of action. Since they have been pre-optimized by nature, these compounds are typically closer to a drug candidate than a synthetic lead, thus requiring less optimization and shorter time when found as ‘hits’ in screening programs.”

The team has also focused on agreements with strategic collaboration partners as vital components to the strategy. Biosortia has recently entered into several collaboration agreements with NOAA, Analyticon and exclusive harvesting relationships, just to name a few. Several others will be advanced by the end of January. Biosortia’s cooperative research and development agreement (CRADA) with NOAA’s Center for Human Health Risk at Hollings Marine Laboratory provides a 5-year framework for research and development regarding the analysis and purification of novel bioactive compounds. According to NOAA’s Technology Partnerships Office, “Success will result in the commercial development of new and unique chemical compounds from the sea which have benefits to human health, either through disease prevention or new treatments for disease.”

Dr. Peter Moeller, NOAA’s Research Scientist who leads the Toxins Natural Products Program stated after analyzing fractions of Biosortia’s biomass, “Coupling NOAA’s mission of characterizing toxins affecting environmental and/or human health with Biosortia’s drug discovery focus turns one man’s toxin into another’s chemotherapeutic. The microorganisms analyzed in the Biosortia biomass identified more unique activity than I have seen in my 30 year career. The volumes achieved from a single harvest delivered an equivalent of 30 years of accumulation. This could materially change the landscape for natural products drug discovery research.”

As of December 31, 2012, Biosortia has identified more than 30 bioactive candidate compounds (hits) from a fresh water eutrophic lake consortium. Therapeutic areas of focus include treatments for cancer, infectious diseases, inflammation and neurological disorders. In addition, more than a dozen of its patent protected compounds are in initial evaluation stage within Eli Lilly’s Open Innovation Drug Discovery Program.

Dieck states, “Looking forward, it is with great optimism. We have a great team built around mutual respect, deep experience, and a desire to succeed and make a difference. We are aligning with the right partners and collaborators to execute our strategy with speed and discipline to provide Pharma with much high quality & diverse compounds vs. “me-too” drugs than they have had in the past 10 years. We are excited about what this company can accomplish, not only for its shareholders but also for the millions of people who have been diagnosed with various forms of chronic diseases who are looking for Pharma to identify better ways to help them extend their lives or live a more productive life. Biosortia can play a big role in identifying compounds that can help Pharma achieve these goals. I am looking forward to the challenge and opportunity to build an industry leading drug discovery company.”

Via EPR Network
More Healthcare press releases

Global Health Progress Applauds HIV-Prevention Medicine Trial, Encourages Access to Medicines in Developing Countries

The New England Journal of Medicine recently released the results of a ground-breaking trial of an HIV-prevention method called oral pre-exposure prophylaxis (PrEP). Data from the trial revealed an almost 44 percent reduction of new HIV infections among participants who took the antiretroviral tablet daily to prevent HIV, compared to those who took the placebo pill.

Participants in the study included 2,499 HIV-negative gay men, transgender women, and other men who have sex with men (MSM) from Peru, Ecuador, Brazil, South Africa, Thailand and the United States; these were randomly chosen to receive the antiretroviral (ARV) drug TDF/FTC (brand name Truvada) or a placebo pill. Regular HIV tests were administrated throughout the study. At the end of the trial, 36 participants who took Truvada had become infected, compared to 64 of the participants who took the placebo pill.

Similar trials are currently being conducted among heterosexuals in Africa and injection drug users in Thailand. Additionally, a trial of a similar ARV in gel form is currently being tested in three US cities, Pittsburgh, Boston and Birmingham, Alabama.

Global Health Progress is encouraged by the outcome of this trial, as it could lead to the prevention of HIV in developing countries and around the world. However, additional funding is needed not only to continue developing drugs like this, but to increase access to medicines around the world. As the world of medicine continues to advance, it is the responsibility of the entire international community to facilitate access to medicines. Success depends on all sectors working in partnership; not only to make medicines more accessible, but also to ensure continued innovation into new medicines for the treatment and prevention of all diseases.

Research-based biopharmaceutical companies help the fight against the HIV/AIDS epidemic by providing millions of doses of anti-retroviral drugs at discounted prices and, in some cases, for free to patients in developing countries. These donation programs for Least Developed Countries and sub-Saharan Africa, together with programs for lower and middle income countries, apply to more than 87 percent of all people living with HIV/AIDS worldwide.

About Global Health Progress:
Global Health Progress also supports efforts to raise awareness and mobilize resources to address health challenges in the developing world by bringing local leaders together with international health experts, policymakers, donor governments, and the private sector. www.globalhealthprogress.org; twitter.com/globalhealth;facebook.com/pages/Global-Health-Progress/124850684219049; linkedin.com/groups?home=&gid=2972068

Via EPR Network
More Healthcare press releases

Mice May Hold Key To Parkinson’s Disease

Recently, scientists at the Weill Cornell Medical School were able to recreate the symptoms of Parkinson’s disease in mice, leading some to believe that a breakthrough in treating the ailment could be just around the corner.

According to a study in the journal Nature Neuroscience, the research involved creating an animal model of Parkinson’s in mice so that scientists can focus on preventing the progression of the disease rather than just on treating its symptoms.

“This research is a huge step for the Parkinson’s community,” says Kay Mixson Jenkins, author of Who Is Pee Dee? Explaining Parkinson’s Disease to a Child. “With efforts like these, Parkinson’s patients have hope that funding and time are going into meaningful steps towards an eventual cure.”

Ms. Jenkins, founder of the non-profit Parkinson’s in the Park, was diagnosed with the disease when she was just thirty-four. She wrote Who Is Pee Dee? for kids who may be asking, “What is Parkinson’s disease?” or, “What are Parkinson’s disease symptoms?”

The book follows a young boy named Colt as he tries to deal with his mother’s illness. It’s the kind of story Ms. Jenkins hopes will be made obsolete by the research being done with mice at Weill Cornell.

“I hope that researchers continue to get funding both private and public,” says Ms. Jenkins, whose book includes a discussion of some of the following symptoms:
• The constant fatigue created by the struggle to control body movement.
• The loss of coordination when doing even simple tasks
• The anger and resentment that can come from feeling overwhelmed

For more information, contact the author directly via kmj@ParkinsonsInThePark.org.

(Who Is Pee Dee? Explaining Parkinson’s Disease to a Child by Kay Mixson Jenkins; illustrated by Richard Morgan; ISBN: 978-0-9819129-0-5; $12.95; 33 pages; 8” x 8”; hardcover; UCB, Inc.)

Via EPR Network
More Healthcare press releases

Britons Play Russian Roulette With World’s Deadliest Disease – The Malaria

According to new research* carried out by Lloydspharmacy, the UK’s leading community pharmacy chain, around 2.1million British holidaymakers and travellers are ignoring the need to protect themselves against malaria.

lloydspharmacy

This may explain the alarming rise in the number of cases found in the UK, with the British Medical Journal reporting a 30% rise in malaria cases in the UK over the last 15 years**.

According to the new survey of over 1000 people, 25% had travelled to a malaria hotspot in the last five years, with the African continent the most popular of these destinations (11%). The research also found that 19% of these intrepid adventurers either ignored the risk of malaria, or abandoned their malaria medication during the danger period. Despite malaria being one of the leading causes of disease and death in the world, with an estimated 300-500 million new cases worldwide every year, resulting in 1.5 to 2.7 million deaths***, Lloydspharmacy found 9% of men and 5% of women simply relied on less effective measures like mosquito repellent, nets or Vitamin B to protect themselves from the potentially deadly disease. A worrying 11% did not even realise that they had travelled to a malarial hotspot.

The release of these findings coincides with the launch of a new complete range of prescription only anti-malarial pills which are available through the Lloydspharmacy’ Online Doctor. This is one of only a few online services of its kind and does not require a visit to a GP. This service is designed to encourage travellers to stock up on the necessary anti-malaria pills before travelling

Chris Frost, Head of Medicines at Lloydspharmacy said “We are far too complacent about the risks of malaria and as a result we have one of the worst track records amongst industrialised countries for bringing this disease home from our holidays. Our new online malaria pills service aims to encourage holidaymakers to protect themselves by making it as easy as possible to access the necessary malaria pills.

“Unfortunately all it takes is just one bite from an infected mosquito to contract malaria and it can be deadly if not treated. However, buying the medication isn’t enough – it will do little to protect travellers unless they follow the instructions carefully.”

The Lloydspharmacy online malaria service involves the customer completing an online questionnaire which is screened by a GP from Dr Thom. If the customer meets appropriate criteria, a prescription is issued and medication distributed with advice on how to take the medication to best effect.

* ICM Survey, Sample 1040, fieldwork done 12th – 14th December 2008
** A Health Protection Agency study identified 6,753 cases of falciparum malaria diagnosed in the UK between 2002 and 2006. This is a 30% increase over the last 15 years, according to the British Medical Journal.
*** Netdoctor.co.uk

About Lloydspharmacy
Lloydspharmacy has around 1700 pharmacies across the UK. These are based predominantly in community and health centre locations. The company employs over 16,000 staff and dispenses over 145 million prescription items annually. Lloydspharmacy is a community pharmacy with primary care at the heart of its business. This is why it has launched a range of products aimed at improving community health such as affordable blood pressure monitors and allergy relievers, as well as a suite of convenient professional health check services including free blood pressure and diabetes testing, and cholesterol and heart checks in the comfort of a private consultation room.

Lloydspharmacy is the trading name of Lloydspharmacy Ltd, a wholly owned subsidiary of Celesio AG based in Stuttgart. Celesio is the leading pharmaceutical distribution company in Europe and is represented in 16 countries. With its three divisions, Patient and Consumer Solutions, Pharmacy Solutions and Manufacturer Solutions, the group covers the entire scope of pharmaceutical trade and pharmaceutical-related services.

Via EPR Network
More Healthcare press releases

Brits Could Be Waiting Too Long To Do Something About Their Health – Reports PruHealth

PruHealth’s bi-annual Vitality Index* – which tracks the nation’s health trends across stress, exercise, diet, smoking, health knowledge and check-ups – has shown that it would take being diagnosed with a health condition to encourage the 79% of people in the UK to improve their health and fitness.

The Vitality Index also shows a distinction between what UK adults consider the biggest health concerns facing the nation and their own individual health concerns. For example, while obesity was considered the biggest health issue facing the nation, from an individual standpoint, cancer was the greatest health concern nationally. Inability to stop smoking and alcohol abuse made it into the top 5 biggest health issues facing the nation; however these concerns were replaced by stress and Alzheimer’s disease on the list of individual health concerns. Conversely, poor diet and nutrition was considered one of the biggest health concerns facing the nation by almost one fifth of UK adults (19 per cent), but only 8 per cent saw it as an individual health concern.

Although people in the UK appear to be clear on the big issues that are facing the health of the nation (with 81 per cent of people knowing what they should and should not do to be healthy), when it comes to translating this knowledge into healthy behaviours, people appear to be struggling. Only a fifth exercise the recommended 5 days a week or more, and just under a quarter eat five portions of fruit and vegetables a day.

Shaun Matisonn, CEO at PruHealth, said: “The most concerning figure here is undoubtedly the 79 per cent of people who will wait until they are diagnosed with an illness before making any attempt to improve their health and fitness, rather than making a lifestyle change now in order to prevent being diagnosed with an illness in the future.

“Finding a way to motivate a change in lifestyle is the biggest hurdle we face as a society, but using incentives to encourage people to look after their health and wellbeing is an extremely powerful motivator.”

Commenting on the findings, Dr David Grainger, Senior Fellow, Cambridge University, said: “Even though three-quarters of people see the health of themselves and their loved ones as a key priority, for the majority it would take diagnosis of ill health to motivate any significant change of lifestyle. It is hard to over-estimate how big a hurdle this is to promoting change. It is disappointing to see that only 13 per cent of respondents had regular health checks, despite the emphasis of the public health message on prevention rather than cure.

“Interestingly, though, more than half of the population say they would change their lifestyle in response to rewards and incentives. Giving serious thought to incentives for a healthy lifestyle must therefore move higher up the public health agenda.”

*The research was carried out on behalf of PruHealth, the insurer that rewards policyholders for engaging in healthy behaviour, by Ipsos MORI. A nationally representative sample of 3,034 GB adults were questioned online in January 2009. Results are weighted to be representative of the GB adult population. Seasonal variations may affect some responses.

About PruHealth
PruHealth was launched in October 2004 as a joint venture between Prudential and Discovery Holdings from South Africa. Since launch, PruHealth has grown quickly. It now covers over 190,000 lives and in a sample of its individual customers, one third said they had changed their behaviour for the better because of its Vitality reward scheme which encourages policyholders to look after their health.

Via EPR Network
More
Healthcare press releases

Hayfever Misery To Hit One In Two People By 2060 Says Lloydspharmacy

New images released by Lloydspharmacy show how the UK’s hayfever time bomb is set to explode within the coming years. Currently, the condition affects around a quarter of the UK population, one of the highest prevalence rates for hayfever in the world. By 2040, up to 28 million people will have hayfever due to severe pollen seasons caused by climate change.

City-dwellers will be worst affected by hayfever as warmer summers will intensify air pollution which affects the respiratory tract and allergenicity of pollens. In 50 years time, it is likely that almost three quarters of the population of London will be affected by hayfever whilst almost half of the population of East Anglia, including Cambridge and Norwich, will have hayfever by 2040. North Scotland has been deemed the best place to live for people who want to avoid hayfever with only a third of the population forecasted to be affected by 2060.

As hayfever is already one of the most common forms of allergy, with almost 12 million people in the UK affected, Lloydspharmacy has made its full report and hayfever maps of the UK available for sufferers to download through its website.

Chris Frost, head of medicines at Lloydspharmacy, said: “Increasingly we are going to need treatments which help people to reduce their susceptibility to hayfever in the first place rather than simply alleviate the symptoms.

“A study conducted by the National Pollen and Aerobiology Research Unit, and published online by the Current Medical and Research Opinion concluded that the Lloydspharmacy Hayfever Reliever significantly reduced the main symptoms of hayfever – sneezing, runny nose, watering eyes and an itchy palate. In fact it’s so effective some people may feel a reduction in hayfever symptoms after using it just a few times. This device has been clinically proven to help to reduce susceptibility to some types of pollens, making it very useful for the severe pollen seasons forecast over the next ten to fifty years.”

UK areas least susceptible to increases in allergenic pollen loads include coastal areas, especially in the west. The further north one goes, the shorter the growing season and the shorter the pollen seasons, causing less misery for hayfever sufferers. Highland and moor land areas are good places for hayfever sufferers as the type of vegetation there produces less pollen.

About Lloydspharmacy
Lloydspharmacy has around 1700 pharmacies across the UK. These are based predominantly in community and health centre locations. The company employs over 16,000 staff and dispenses over 145 million prescription items annually. Lloydspharmacy which is a community pharmacy has primary care at the heart of its business. This is why it has launched a range of products aimed at improving community health such as affordable blood pressure monitors and allergy relievers, as well as a suite of convenient professional health check services including free blood pressure and diabetes testing, and cholesterol and heart checks in the comfort of a private consultation room. Lloydspharmacy is the trading name of Lloydspharmacy Ltd, a wholly owned subsidiary of Celesio AG based in Stuttgart. Celesio is the leading pharmaceutical distribution company in Europe and is represented in 16 countries. With its three divisions, Celesio Wholesale, Celesio Pharmacies and Celesio Solutions, the group covers the entire scope of pharmaceutical trade and pharmaceutical-related services.

Via EPR Network
More
Healthcare press releases

Recent Research Published By The American Journal For Medicine Showed 87% Of Diabetics Either Saw A Complete Cure Or Improvement After Weight Loss Surgery

As the focus on the nation’s expanding waistlines grows, medical experts now believe that weight loss surgery can completely eliminate all types of Diabetes.

The UK’s number one weight loss surgery provider, The Hospital Group, has seen outstanding long-term results for its gastric band patients over the last three years. Of the 106 gastric band operations performed in January 2007, the total weight loss was a massive 300 stone. Obesity is the main risk factor for Diabetes, so sustained weight loss on this level goes a long way towards fighting the condition, which affects 2.5 million people in the UK, according to Diabetes UK.

The research published by the American Journal for Medicine showed that following obesity surgery, 87% of diabetics either saw a complete cure or improvement.

David Ross, Chief Executive of The Hospital Group, said: “More and more people are choosing to have obesity surgery with The Hospital Group and it’s fantastic because people see results so quickly, which gives them the get up and go to live healthier lifestyles – some free from Diabetes. You wouldn’t think it, but Australia is the gastric band capital of the world. Their government recognises the long-term savings it can make by funding obesity surgery on their national healthcare system – and in the same way, obesity surgery in the UK is saving the NHS money by curing Diabetes patients, which is currently costing the NHS £1m an hour.”

The huge surge in demand for obesity fighting treatments such as Gastric Bands, Balloons and Bypasses from The Hospital Group has more than doubled in the last year, rising from 111 operations in February 2008 to 225 in the same month in 2009. Continuing the trend, enquiries into gastric band surgery have risen by almost 25% from 727 in February 2007 to 963 in February 2009. Health-conscious surgery-seekers in February 2008 made 815 enquiries into The Hospital Group’s obesity surgery.

The Hospital Group is committed to providing the very highest standards and all procedures are performed by an expert medical team in state-of-the-art facilities that are second to none. Since The Hospital Group was established in 1992, it has grown from a small pharmaceutical company to one of the UK’s foremost cosmetic surgery providers, and the same high standards remain to this day. For further information of The Hospital Group’s range of gastric procedures, surgery-seekers should visit the website www.thehospitalgroup.org or call our patient care coordinators on 0845 762 6727.

Via EPR Network
More 
Healthcare press releases

Who Is Pee Dee?

The recent Frontline special “My Father, My Brother, and Me” explored the effect that Parkinson’s disease (PD) has on the children of PD patients, a topic also explored in a recently published book by Parkinson’s in the Park founder Kay Mixson Jenkins.

Ms. Jenkins was diagnosed with PD at the age of thirty-four and has been an advocate for research and patient support since. Her book, Who Is Pee Dee? Explaining Parkinson’s Disease to a Child, addresses the impact the disease has on the relatives of those with PD—especially their children.

Talking with a child about a disease that manifests itself through physical symptoms can be difficult because of the mental toll it also takes on a family. It’s a conversation that more and more people are having with their kids. More than six million people worldwide have been diagnosed with PD, and one in ten patients diagnosed are under the age of fifty.

In Who Is Pee Dee?, Ms. Jenkins uses a stuffed Panda bear named Pee Dee and a boy named Colt to answer many of the most common questions that kids have about the chronic illness:

• What is Parkinson’s disease?
• Why is Mommy or Daddy upset?
• What can I do to help?
• Why is Mommy moving slowly?

“As I’ve gotten older,” says Ms. Jenkins, “the disease has progressed. There will come a day when I’ll have to use a cane or a wheelchair, but I am determined to make my grandchildren proud of their ‘Muffin.’ I’m not going down without a fight.”

Ms. Jenkins says that it is crucial for people living with Parkinson’s to have resources to help them adjust to their new lives. Who is Pee Dee? includes pages of resources for adults, including websites, support groups and more.

Kay Mixson Jenkins is the Georgia state co-coordinator for the Parkinson’s Action Network, leads the Effingham County Parkinson’s support group and was selected as a Parkinson’s patient advocate for UCB, Inc.

For more information, contact the author directly via kmj@parkinsonsinthepark.org.

(Who Is Pee Dee? Explaining Parkinson’s Disease to a Child by Kay Mixson Jenkins; illustrated by Richard Morgan; ISBN: 978-0-9819129-0-5; $12.95; 33 pages; 8” x 8”; hardcover; UCB, Inc.)

Via EPR Network
More Healthcare press releases